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tically significant for both feet (p0.001). Hyperkeratosis of both feet, evaluated by
the doctor, significantly improves after 4 weeks of treatment. The efficacy score
measured by the patient is 16.4 ( 4.8) on inclusion. Measured under the same
conditions, it is 7.7 ( 3.2) at 4 weeks. The difference is statistically significant
(p0.001). Treatment compliance is good since 89% confirm that they respected the
dosage, a trend confirmed by the fact that 94% of subjects say that they are satisfied
with the product.CONCLUSIONS: By means of a validated score (XAS) and a patient
evaluation scale, the efficacy of Pedimed in treating the diabetic foot is confirmed.
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OBJECTIVES: The objective of this study was to estimate a prevalence of diabetes
mellitus (DM) among patients with micro- and macrovascular complications in
Poland, like angina pectoris, myocardial infarction (MI), stroke, lower limb isch-
emia, end-stage renal disease (ESRD), and their consequences like heart failure,
visual disorders or amputations. METHODS: The estimation was based on obser-
vational studies, which were identified by searching medical databases and Polish
registries. Publications were selected in a specific order, to ensure that included
data are the most representative for Polish population. Firstly, studies conducted in
Polish settings were included and, if no reliable publications were found, European,
non-European Caucasian and other (not specified) population were analyzed. Pop-
ulation based registries were considered as the most appropriate type of data.
When no registry was available systematic reviews of observational studies were
included. If systematic review was not available – data from clinical studies were
taken into account. RESULTS: According to polish registries, DM was present in
28% of patients with non-ST-elevation MI, 20% of patients with ST-elevation MI,
22% of patients with unstable angina and 22% patients with ESRD. The results of
two studies regarding Polish population indicate that 15.3% of patients with stable
angina pectoris suffer from DM. The results of studies coming from European coun-
tries identified by literature search showed that DM was diagnosed in 26.2% of
patients with heart failure, 21.5% of patients with stoke, 40% of patients hospital-
ized for peripheral artery disease, 52.8% of patients with lower-extremity amputa-
tion and 67.1% of patients with non-traumatic amputations. Diabetes was present
in 34.9%, 9.4% and 7.1% of patients with retinopathy, vision disorders and blindness
respectively. CONCLUSIONS:DM often co-exists with vascular disorders in Poland.
It affects 15% of patients with macrovascular complications and more than 20% of
patients with microvascular complications.
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OBJECTIVES: To evaluate the effect of A1C variability on the risk of developing new
diabetes in healthy adults in Japan. METHODS: Population-based, retrospective
cohort from 2005 to 2008 in Tokyo, Japan. In healthy adults not taking diabetes
medication and with lower than 6.5 of HbA1c at baseline, we measured annually
the serum HbA1c and calculated the annual visit-to-visit variability. RESULTS: At
baseline, 14,764 people (49% female) with a mean age of 50 years old (SD: 12 years,
range: 23 to 92), a mean fasting plasma glucose (FPG) level of 98.4 mg/dl (SD: 9.3
mg/dl) and a mean HbA1c level of 5.3 % (SD: 0.4 %) had annual check-ups over 4
years. Using the multivariate logistic regression, the A1C variability (odds ratio
(OR): 7.8 for highest quantile interval ( 0.16%)) versus the lowers quantile (0.08
%), 95%CI: 4.8 – 12.8) and the baseline A1C (OR: 43.3 for group with 6.0 – 6.4 % of A1C
versus with 5.0 %, 95% CI: 10.4 – 181.4) were independently predictive of new
diabetes after adjusting for the other potential risk factors. FPG (OR: 1.1, 95%CI: 1.1
– 1.2) and Smoker (OR: 1.6, 95%CO: 1.2 – 2.3) also significantly related to develop the
new diabetes.CONCLUSIONS:Visit-to-visit variability in A1C independently added
to the baseline A1C in predicting the risk of developing new diabetes for the healthy
adults.
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OBJECTIVES: Beta cells in the pancreas are responsible for secreting insulin in
response to increases in blood glucose. Proinsulin C-peptide (C-peptide), co-se-
creted with insulin, is a marker for beta cell function. C-peptide levels at type 1
diabetes (T1D) diagnosis and rate of decline (ROD) post diagnosis are important
when evaluating the potential beta cell-preserving therapies to maintain better
glycemic control and reduce complications. Because little is known about factors
that affect C-peptide levels at diagnosis and ROD, we aimed to summarize known
factors. METHODS: We conducted a systematic review of literature in PubMed
(English only) from 1987 using the following key words alone and in combination:
type 1 diabetes, c-peptide, rate of decline, concentration, epidemiology, residual
beta cell function, diagnosis. Additionally articles were identified from the refer-
ence lists of selected journal articles. RESULTS: The review indicated that: 1) De-
cline of beta-cell function begins years before T1D diagnosis; 2) At diagnosis stim-
ulated C-peptide concentrations range from 0.320.26 pmol/mL (meanSD) to
1.40.8 pmol/mL (meanSD); 3) Stimulated C-peptide ROD can range from -0.00 to
-0.01 pmol/mL/month; 4) Lower C-peptide concentrations at diagnosis are partly
explained by younger onset age, time since diagnosis, genetic factors and a high-
titer presence of islet cell autoantibodies; and 5) Intensive therapy to treat T1D of
3 insulin injections daily reduces the C-peptide level after 1 year by 0.210.03
pmol/mL versus 0.150.02 pmol/mL for less intensive treatment of 1-2 injections.
CONCLUSIONS: Understanding the factors that influence C-peptide ROD may help
researchers develop strategies which address heterogeneity of response to ther-
apy, resulting in improved glycemic control and reduction in complications such as
ketoacidosis, neuropathy or nephropathy. Including parameters for C-peptide and
its ROD in pharmacoeconomic models may help estimate the burden of these
complications in T1D, and help quantify the benefits of preserving beta cells.
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OBJECTIVES: The safety and efficacy of exenatide BID (exenatide) compared to
insulin glargine (glargine) has been studied in clinical trials and use of exenatide
has been associated with reductions in A1C and weight. This study examined the
clinical outcomes of exenatide versus glargine in patients with type 2 diabetes in a
‘real-world’ ambulatory care setting. METHODS: A retrospective analysis was con-
ducted using the General Electric electronic medical record database to select ex-
enatide (n4,494) and glargine (n5,424) cohorts. These cohorts were propensity-
score matched to control for baseline demographic, clinical, and resource use
variables (2,683 matched pairs). Matched cohorts were compared using paired t-
tests and nonparametric tests as appropriate. The effectiveness endpoints were
changes in A1C (primary endpoint), weight, body mass index (BMI), blood pressure
(BP), lipid levels, and hypoglycemia rates. RESULTS: The matched exenatide and
glargine cohorts had comparable age (58 vs. 58 years), females (55% vs. 53%), and
baseline clinical characteristics. In a 12-month follow-up period, the exenatide
cohort achieved greater mean (SD) reduction in A1C (-0.66% [1.5] versus -0.41%
[1.7], P0.01), weight (-2.6 [6.8] vs. -0.2 [9.2] kg, P0.01), BMI (-0.9 [2.6] versus
-0.1 [2.7] kg/m2, P0.01), and systolic BP (-1.8 [17] vs. -0.3 [18] mmHg, P0.01).
More exenatide-treated patients reached the A1C goal of7% (46% vs. 36%, P0.01).
There were no clinically significant differences in diastolic BP, lipid levels, and
hypoglycemia rates between cohorts. CONCLUSIONS: Exenatide-treated patients
experienced significantly greater reductions in A1C, weight, BMI, and systolic BP
than the glargine cohort. These results demonstrated the clinical effectiveness of
exenatide compared to glargine in a large, diverse, ‘real-world’ patient population
treated in the ambulatory care setting.
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OBJECTIVES: According to HTA reports regarding long-acting insulin analogues
(LAIA) these drugs should be reserved for use in selected diabetic patients only. In
line with recent knowledge LAIA in Poland are planned to be reimbursed in frame-
work of therapeutic programme (LAIA-TP). This study assess the impact of this
decision on public health-payers budget. METHODS: The analysis was perfomed
using modelling technique, based on systematic review of LAIA, Polish epidemio-
logic and costing data. Two scenarios were compared: (A) LAIA not reimbursed, (B)
LAIA reimbursed for patients with episodes of severe hypoglicaemia (after 6
months reimbursement continued only in patients successfully treated). In each
scenario annual costs of insulinotherapy, monitoring and tretament of hypoglicae-
mia were estimated in 3-years time horizon. Model was run by having the current
patient cohort progress through the model accompanied by the addition each year
of a new cohort of eligible patients. Extreme scenario sensitivity analyses were
performed. RESULTS: The expected number of diabetic patients eligible for LAIA
would be 12,611 in the 1st year, and each year 661 “new” patients will meet inclu-
sion criteria. Only 25% patients with type 1 and 30% patients with type 2 diabetes
will be successfully treated with LAIA. The introduction of LAIA-TP is expected to
increase public-payers expenditure in years 1st -3th by 12,168,582, 7,972,737 and
8,321,552 PLN, respectively (1 PLN0.25 EURO, 2011). Such an increase in cost would
be associated with acquisition cost of LAIA and would be only partially compen-
sated by lower costs of monitoring and treatment of hypoglicaemia. Depending on
assumptions about population and effectiveness of LAIA the additional expendi-
tures of public payer varies between 11,295,941- 8,962,648 PLN, 7,219,765-9,627,449
PLN and 7,556,552-10,505,485 PLN in 1st, 2nd and 3rd year, respectively.
CONCLUSIONS: Budget impact analysis indicates that reimbursement of LAIA-TP
seems to be affordable to the budget holder.
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OBJECTIVES: Hyperglycaemia is a frequent condition in hospitalizations for acute
conditions, not always correlated with a previous presence of diabetes. Patients
with hyperglycaemia experiment a worse prognosis, with increased mortality,
complications and a longer hospital stay than normal ones. Several evidences in
A475V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
